Literature DB >> 10394589

New treatment strategies for malignant gliomas.

N G Avgeropoulos1, T T Batchelor.   

Abstract

Although survival in patients with malignant gliomas remains limited, there is renewed optimism with the emergence of novel treatment strategies. Cytotoxic agents such as temozolomide and CPT-11 have shown promising clinical activity. Biological treatments for brain tumors, including antisense oligonucleotides, gene therapy, and angiogenesis inhibitors, are also being evaluated in clinical trials. Delivery strategies have been developed to overcome challenges presented by the blood-brain barrier. These noteworthy treatments, alone or in combination, may ultimately prolong survival and enhance quality of life in this group of patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10394589

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  32 in total

1.  Evidence for ectopic aerobic ATP production on C6 glioma cell plasma membrane.

Authors:  Silvia Ravera; Maria Grazia Aluigi; Daniela Calzia; Paola Ramoino; Alessandro Morelli; Isabella Panfoli
Journal:  Cell Mol Neurobiol       Date:  2010-11-17       Impact factor: 5.046

2.  Fluorescence Molecular Imaging and Tomography of Matrix Metalloproteinase-Activatable Near-Infrared Fluorescence Probe and Image-Guided Orthotopic Glioma Resection.

Authors:  Li Li; Yang Du; Xinjian Chen; Jie Tian
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

3.  Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme.

Authors:  Chawan Manaspon; Norased Nasongkla; Khuanjit Chaimongkolnukul; Pinunta Nittayacharn; Ketpat Vejjasilpa; Kanchana Kengkoom; Atthaporn Boongird; Suradej Hongeng
Journal:  Pharm Res       Date:  2016-08-05       Impact factor: 4.200

4.  Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide.

Authors:  Ana P Montaldi; Elza T Sakamoto-Hojo
Journal:  Clin Exp Med       Date:  2012-07-25       Impact factor: 3.984

5.  Mechanisms of the increase in the permeability of the blood-tumor barrier obtained by combining low-frequency ultrasound irradiation with small-dose bradykinin.

Authors:  Chun-yi Xia; Zhen Zhang; Yi-xue Xue; Ping Wang; Yun-hui Liu
Journal:  J Neurooncol       Date:  2009-02-22       Impact factor: 4.130

6.  Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture.

Authors:  Mario Luiz Conte da Frota; Elizandra Braganhol; Andrés Delgado Canedo; Fabio Klamt; Miriam Anders Apel; Beatriz Mothes; Cléa Lerner; Ana Maria Oliveira Battastini; Amélia Teresinha Henriques; José Cláudio Fonseca Moreira
Journal:  Invest New Drugs       Date:  2008-05-03       Impact factor: 3.850

7.  Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines.

Authors:  Fernanda B Morrone; Maria C Jacques-Silva; Ana P Horn; Andressa Bernardi; Gilberto Schwartsmann; Richard Rodnight; Guido Lenz
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

8.  EFEMP2 is upregulated in gliomas and promotes glioma cell proliferation and invasion.

Authors:  Long Wang; Qianxue Chen; Zhibiao Chen; Daofeng Tian; Haitao Xu; Qiang Cai; Baohui Liu; Gang Deng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  Boldine: a potential new antiproliferative drug against glioma cell lines.

Authors:  Daniéli Gerhardt; Ana Paula Horn; Mariana Maier Gaelzer; Rudimar Luiz Frozza; Andrés Delgado-Cañedo; Alessandra Luiza Pelegrini; Amélia T Henriques; Guido Lenz; Christianne Salbego
Journal:  Invest New Drugs       Date:  2008-12-03       Impact factor: 3.850

10.  A human brainstem glioma xenograft model enabled for bioluminescence imaging.

Authors:  Rintaro Hashizume; Tomoko Ozawa; Eduard B Dinca; Anuradha Banerjee; Michael D Prados; Charles D James; Nalin Gupta
Journal:  J Neurooncol       Date:  2009-07-08       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.